Guttman-Yassky, E., Brunner, P., Neumann, A., Khattri, S., Pavel, A., Malik, K., … Lebwohl, M. (2018). Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2018.01.016 (Original work published 2018)